Company intelligence / Profile preview

MAAX

San Francisco, California, United States

Ownership: Private
Employees: ~25
Development stage: Other

Overview

MAAX is a biotechnology company focused on developing next-generation therapeutic solutions for oncology and autoimmune diseases. The company leverages its proprietary MAAX platform to identify and optimize novel drug candidates with improved efficacy and safety profiles. Currently in the pre-clinical stage, MAAX is advancing a pipeline of small molecules and antibodies designed to address significant unmet medical needs. The company's approach combines advanced computational biology with traditional drug discovery methods to accelerate the development of transformative medicines.

Therapeutic areas: OncologyImmunology
Modalities: Small moleculeAntibody
Industry: Biotech

Beyond the preview

Go deeper on MAAX.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MAAX.

Explore the full profile